Precigen, Inc. (PGEN) - Form 8-K Summary
Business Context and Reporting Period
Precigen, Inc. filed this Current Report on Form 8-K on August 4, 2026. The filing serves to announce the company's financial results for the quarter ended June 30, 2026, via a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided filing text is a cover page and does not contain specific numerical data. Consequently, values for revenue, profit, cash flow, margins, debt, and liquidity are not available in this document. These figures are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative analysis.
Guidance, Outlook, and Risks
This document does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. The filing explicitly states that the information in the attached exhibit shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the specific revenue and net loss figures for the quarter ended June 30, 2026, in the attached press release (Exhibit 99.1).
- Confirm the company's cash position and runway based on the full financial statements referenced in the press release.
- Review the press release for any updates on clinical trial progress or regulatory milestones, which are typical drivers for Precigen's valuation.
- Check for any new guidance or changes to the company's operational outlook provided in the full press release.